joe-manchin heather-bresch mylan epipen pharma family-enrichment class-analysis
related: _Joe Manchin Master Profile · Big Pharma Bloc
donors: PhRMA · (Mylan — internal family firm)
content-readiness:: ready
The Bresch-EpiPen Scandal and Family Enrichment
Money
Heather Bresch — Joe Manchin’s daughter — served as CEO of Mylan Pharmaceuticals. Under her leadership, Mylan raised the price of the EpiPen from $57 (2007) to $609 (2016) — a 391% increase for a life-saving medication with no significant competitor. Bresch’s compensation reached $18.9 million annually. Manchin’s response when questioned about the pricing: “I’m very proud of her.” The senator represents one of the poorest states in America while his daughter extracted $18.9 million per year by pricing a life-saving drug beyond the reach of families like the ones he represents.
The EpiPen Price Timeline
| Date | Event | Amount | Source |
|---|---|---|---|
| 2007-01-01 | Mylan EpiPen baseline price (2-pack) | $57 | Washington Post |
| 2009-01-01 | Mylan EpiPen price increase | $100 | Washington Post |
| 2013-01-01 | Mylan EpiPen price increase | $265 | Washington Post |
| 2016-09-01 | Mylan EpiPen price reaches peak (2-pack) | $609 | House Oversight Committee |
What changed: Nothing about the product changed. The epinephrine in the EpiPen costs approximately $1. The auto-injector technology was decades old. Mylan raised the price because it could — EpiPen held 90%+ of the market, and families with children who have severe allergies had no alternative. The price increases were pure extraction.
Bresch’s Compensation and Career
CEO compensation (Mylan): $18.9 million annual (at peak)
The MBA scandal: In 2007, it was revealed that West Virginia University had retroactively awarded Heather Bresch an MBA she had not completed. Bresch had earned only 22 of 48 required credits. WVU’s provost resigned over the scandal. The degree was rescinded. At the time, Joe Manchin was Governor of West Virginia — the state that funds WVU. The university’s accreditation was briefly threatened.
Contradiction
West Virginia’s governor’s daughter received a degree she didn’t earn from the state’s flagship university — while her father controlled the state’s budget. Years later, she became CEO of a pharmaceutical company that priced a life-saving medication beyond the reach of West Virginia families — the poorest in America. The Manchin family’s enrichment operates through institutional capture at every level: state government, state university, pharmaceutical industry, and federal Senate.
Manchin’s Pharmaceutical Positions
Despite his daughter’s pharmaceutical career, Manchin has never recused himself from pharmaceutical policy votes:
- Supported Medicare drug price negotiation provisions in the IRA — but only after ensuring the negotiation applied to just 10 drugs initially (a major pharma concession)
- Never supported broader price controls that would have affected the kind of pricing Mylan engaged in
- Did not support importation of cheaper drugs from Canada at the scale reform advocates demanded
- Career pharmaceutical industry contributions: included in broader healthcare donor totals
Money
The EpiPen scandal is the Manchin family’s core contradiction in miniature: a senator from the poorest state, whose daughter became a multimillionaire by making a life-saving medication unaffordable for families in states like his own. Manchin’s “pride” in Bresch’s career is the tell — he sees pharmaceutical extraction not as a systemic failure but as a family achievement. The donor-class perspective is the family perspective.
Sources
- House Oversight Committee: Reviewing the Rising Price of EpiPens hearing (Tier 1)
- Testimony of Mylan CEO Heather Bresch (Tier 1)
- Washington Post: CEO at center of EpiPen price hike controversy is Sen. Joe Manchin’s daughter (Tier 2)
- The Intercept: Heather Bresch played direct part in EpiPen price inflation (Tier 2)
- OpenSecrets: Manchin received large campaign contributions from daughter’s company (Tier 1)